Ketamine, a dissociative anaesthetic, has expanded its clinical use beyond anaesthesia to pain management and treatment-resistant depression. As an N-methyl-d-aspartate receptor antagonist, ketamine disrupts the excitatory neurotransmission via interaction with the opioid, alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionic acid receptor and serotonin pathways, contributing to its broad...
Research on psychedelic substances such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT) is gaining momentum.1 However, the possible effects of these substances on systemic functions such as endocrine activity, particularly neurotransmitter-regulated glucagon release in pancreatic alpha cells, remain largely unexplored. This commentary aims to address the...